Sign in
Taking people in United StatesPhase 2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Key facts

Who runs it
Neurocrine Switzerland GmbH
Where
Ann Arbor, Atlanta, Aurora, Chicago, Dallas, Hartford, Indianapolis, Minneapolis, Philadelphia, San Francisco, and Seattle, United StatesSee the 11 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Jul 2026
Expected to end
Mar 2028
Type of study
Interventional
Treatments tested
  • Crinecerfont
Record updated
16 September 2026

Who can take part

Age
3 months to 47 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency (21-OHD)
  • Have received at least 3 months of hydrocortisone treatment before Day 1, with a stable dose for at least 4 weeks before screening
  • Have a body weight of at least 4.5 kilograms (kg) at screening
  • Have a newborn screen that is otherwise normal except for elevated 17-OHP or any other abnormality on newborn screen that was cleared upon evaluation by a pediatric specialist

Who cannot take part

  • Have any condition besides CAH that requires chronic daily therapy with orally administered steroids
  • Have any other clinically significant medical condition or chronic disease; Note: Other protocol-defined inclusion and exclusion criteria may apply
  • Have a known or suspected diagnosis of any of the other forms of classic CAH

Where in United States

  • Ann Arbor, MichiganHospital not named in the registryTaking people
  • Atlanta, GeorgiaHospital not named in the registryTaking people
  • Aurora, ColoradoHospital not named in the registryTaking people
  • Chicago, IllinoisHospital not named in the registryTaking people
  • Dallas, TexasHospital not named in the registryTaking people
  • Hartford, ConnecticutHospital not named in the registryTaking people
  • Indianapolis, IndianaHospital not named in the registryTaking people
  • Minneapolis, MinnesotaHospital not named in the registryTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryTaking people
  • San Francisco, CaliforniaHospital not named in the registryTaking people
  • Seattle, WashingtonHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to <4 years of age with CAH.

The group in the trial

  • CrinecerfontTreatment being tested

    Participants with CAH will receive crinecerfont.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Record updated
16 September 2026